Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)是一家临床阶段生物技术公司，目前股价为每股16.43美元。该公司宣布了2024年年度股东大会的结果，并提供了与Palvella Therapeutics, Inc.计划合并的最新进展。根据 InvestingPro 的数据，该公司在过去十二个月面临重大挑战，收入下降97%，但仍保持较强的流动性，流动比率为4.82。

Limited (DPMC) has launched the Bajaj Pulsar N160, the third motorcycle model produced under the Local Value Addition (LVA) programme at the DPMC Head Office in Battaramulla yesterday. This launch ...

David Pieris Motor Company (Lanka) Limited (DPMC) announces the launch of the Bajaj PulsarN160, the third motorcycle model produced under the Local Value Addition (LVA) programme.

Pieris Pharmaceuticals’ long-standing immuno-oncology alliance with Servier is being dissolved after a clinical trial of the lead drug in the alliance revealed a safety concern. In a Securities ...

BASEL, Switzerland – 3rd 2024 - Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized ...

Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized neoantigen cancer immunotherapies ...

390.00 LKR-5.00-1.27% ...

E-W Information Systems Limited (EWIS), a trailblazer in tech solutions, made waves at the Africa Tech Festival 2024, held ...

Banking stocks saw mixed interest: Hatton National Bank (up at 233.50), Sampath Bank (down at 97.50), Commercial Bank (down ...

The Attorney General yesterday informed the Supreme Court that the Cabinet of Ministers has recommended not to re-conduct the Grade 5 ...

The settlements in the Mahaweli scheme started in 1978. Because of Mahaweli, Tamils in the Eastern province lost two-thirds ...

This winter, elevate your living room with chic, low-maintenance plants that can survive Mumbai weather easily ...